Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 3/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | CTRC | Q99895 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495762 | 0.89 | LDHA (0.50) | LDHACCR1CCR5CCR8HDAC6 | |
| SCHEMBL310421 | 0.85 | TDP1 (0.42) | CCR1CCR5CCR8HDAC6CYP3A4 | |
| SCHEMBL15706893 | 0.85 | CYP3A4 (0.40) | CCR1CCR5CCR8HDAC6CYP3A4 | |
| SCHEMBL3474997 | 0.84 | DHODH (0.54) | LDHACCR1CCR5CCR8HDAC6 | |
| SCHEMBL310999 | 0.82 | NPC1 (0.41) | CYP3A4CYP2A6SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2171200 | 0.82 | RAB9A (0.44) | LDHACCR1CCR5CCR8HDAC6 | |
| SCHEMBL2273188 | 0.82 | LDHA (0.44) | LDHAP4HA1P4HTMCTRCSMN1; SMN2 | |
| SCHEMBL358035 | 0.82 | LDHA (0.58) | LDHACCR1CCR5CCR8HDAC6 | |
| SCHEMBL3473972 | 0.82 | LDHA (0.55) | LDHACCR1CCR5CCR8HDAC6 | |
| SCHEMBL3063243 | 0.81 | P2RX3 (0.44) | LDHACCR1CCR5CCR8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896439-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896439-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896439-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2018-02-20 | — | — | US | disclosed |
| US-9849136-B2 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170182057-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-06-29 | — | — | US | disclosed |
| US-9617254-B2 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-04-06 | — | — | US | disclosed |
| US-20160222004-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2016-08-04 | — | — | US | disclosed |
| US-20090163499-A1 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| US-20090163499-A1 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| US-20090163499-A1 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| WO-2009077366-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND /OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077366-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND /OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077367-A1 | NOVEL PYRAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077367-A1 | NOVEL PYRAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077365-A1 | NOVEL IMIDAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20080132494-A1 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| WO-2008055840-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182057-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | LDHA 3999/4885CCR1 1046/4885CCR5 1065/4885 |
| US-20090163499-A1 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX1 | LDHA 4553/4885CCR1 1330/4885CCR5 740/4885 |
| US-20080132494-A1 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX1 | LDHA 3945/4885CCR1 818/4885CCR5 1262/4885 |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | LDHA 4530/4885CCR1 1255/4885CCR5 1058/4885 |
| US-20160222004-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX1 | LDHA 3945/4885CCR1 818/4885CCR5 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.